NOV 13, 2019 9:27 AM PST

The Side-Effects to A Common Blood Cancer Drug

WRITTEN BY: Nouran Amin

In a study published in Scientific Reports, a popular cancer drug, known as ruxolitnib, was found to cause an increased weight gain as well as an increase in liver enzymes and systolic blood pressure.

“Weight gain with ruxolitinib has previously been reported in clinical trials, but our study provides real-world experience regarding the extent of that weight gain,” said Emily J. Gallagher, MD, PhD, the study’s lead author and Assistant Professor of Medicine (Endocrinology, Diabetes and Bone Disease) at the Icahn School of Medicine at Mount Sinai, specializing in onco-endocrinology, the treatment of endocrine complications of oncology treatments. “We recommend that patients who go on this medication and do have an increase in weight get a full metabolic evaluation.”

Researchers from Icahn School of Medicine at Mount Sinai reported in their study that the FDA-approved ruxolitinib, which was the first and most widely prescribed in treating blood cancers, holds strong metabolic effects. Ruxolitinib treats the particular blood cancer group known as myeloproliferative neoplasms (MPNs), which includes myelofibrosis and polycythemia vera. The drug blocks the enzyme Janus kinases (JAK) ½ resulting in the inhibition of blood cell production. Although previous studies have noted the side-effects, researchers are now beginning to understand the long-term consequences of cancer therapeutics on metabolic health.

Learn more about the mechanism of action:

“In contrast to the perception of many health care providers, patients are not going from being underweight to being a normal weight. Instead, a significant number of patients are developing obesity. Based on these results, physicians should be aware of the potential effects, and counsel patients accordingly,” said Dr. Gallagher.

Source: Mount Sinai Health

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 12, 2021
Drug Discovery & Development
Epidural Use Not Linked To Autism
APR 12, 2021
Epidural Use Not Linked To Autism
Epidurals are a form of pain relief during childbirth and is used by more than half of all women in labor. Many women wh ...
APR 27, 2021
Cannabis Sciences
CBD Doesn't Reduce Pain, but Makes it Less Unpleasant
APR 27, 2021
CBD Doesn't Reduce Pain, but Makes it Less Unpleasant
While anecdotal reports tout cannabidiol’s (CBD) utility for pain relief, up until now, there’s been limited ...
MAY 06, 2021
Cannabis Sciences
New CBD Analog Outperforms Regular CBD for Pain Relief
MAY 06, 2021
New CBD Analog Outperforms Regular CBD for Pain Relief
Researchers from Temple University Health System have found that a novel cannabidiol (CBD) analog can reverse pain sensi ...
MAY 17, 2021
Cell & Molecular Biology
Survey Results: Where Is Pluripotent Stem Cell Research Now?
MAY 17, 2021
Survey Results: Where Is Pluripotent Stem Cell Research Now?
Human pluripotent stem cell (hPSC) lines are now commonly used across the globe. In the lab, researchers rely on hPSCs t ...
JUN 24, 2021
Cell & Molecular Biology
The Curiosity About Caterpillar Venom
JUN 24, 2021
The Curiosity About Caterpillar Venom
It seems like Australia is home to some of the world's deadliest animals, like taipan snakes and box jellyfish. Even the ...
JUN 26, 2021
Cancer
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
JUN 26, 2021
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
Research shows that obese patients with cancers including ovarian and melanoma may respond better to a certain kind of i ...
Loading Comments...